"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
LivMOD
1 other identifier
observational
800
1 country
1
Brief Summary
Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 4, 2020
CompletedFirst Posted
Study publicly available on registry
December 31, 2020
CompletedStudy Start
First participant enrolled
January 14, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 18, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 2, 2029
ExpectedFebruary 12, 2026
February 1, 2026
4 days
December 4, 2020
February 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Surgery for a hepato-bilio-pancreatic issue
Patients whom hepato-bilio-pancreatic disease
through study completion, an average of 8 year
Study Arms (3)
Hepato-bilio-pancreatic surgery
Patients whom hepato-bilio-pancreatic surgery is indicated as part of the care
biopsy of the hepatic parenchyma
Patients whom a biopsy of the hepatic parenchyma, one or more hepatic nodules or a loco-regional treatment is indicated as part of the care
Viral chronic infection
Patients with a viral chronic liver disease
Interventions
As part of the treatment, an additional biopsy is executed and blood is drawn.
Blood sample as part of the care
During the hepato-bilio-pancreatic surgery, blood is drawn.
Eligibility Criteria
Population with hepato-bilio-pancratic disease (tumor, viral infection, injury)
You may qualify if:
- Patients
- diagnosed with chronic liver disease (viral or not)
- diagnosed with at least one liver nodule for which a biopsy is planned as part of the care
- for hepatobiliary surgery planned as part of care
- for locoregional treatment for HCC is indicated
- Patients able to receive and understand information relating to the study and give their written informed consent
- Patients affiliated to the French social security system
You may not qualify if:
- Minor patients
- Patients under legal protection,
- Patients subject to legal protection or unable to express their consent,
- Patients in a situation of social fragility,
- Pregnant or breastfeeding woman,
- No signing of informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
PU-PH, Directeur de l'UMR_S1110 Unité Inserm d'affiliation : UMR_S1110
Strasbourg, 67000, France
Biospecimen
Blood sample Cohort 1 and 2 : 1 tube (10ml) of blood Cohort 3 : 10 tubes (10ml) of blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 4, 2020
First Posted
December 31, 2020
Study Start
January 14, 2021
Primary Completion
January 18, 2021
Study Completion (Estimated)
September 2, 2029
Last Updated
February 12, 2026
Record last verified: 2026-02